Rite Aid Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jeffrey Stein

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2.3yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

CEO

Jeffrey Stein (54 yo)

less than a year

Tenure

Mr. Jeffrey Scott Stein is Chief Executive Officer and Chief Restructuring Officer at Rite Aid Corporation since October 16, 2023 and served as its Director. He serves as Chief restructuring officer at Cho...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Matthew Schroeder	CFO & Executive VP	5.2yrs	US$2.75m	0.36% € 27.3k
Jeffrey Stein	CEO & Chief Restructuring Officer	less than a year	no data	no data
Steven Bixler	Chief Accounting Officer & Senior VP	1.3yrs	no data	0.0064% € 493.3
Byron Purcell	Vice President of Investor Relations & Treasurer	no data	no data	no data
Thomas Sabatino	Executive VP & Chief Legal Officer	less than a year	no data	no data
Joy Seusing	Senior VP & Chief Communications Officer	no data	no data	no data
Jeanniey Walden	Senior VP & CMO	1.2yrs	no data	no data
Jessica Kazmaier	Executive VP	5.2yrs	no data	0.16% € 12.5k
Karen Staniforth	Senior VP of Clinical Pharmacy Services & Chief Pharmacy Officer	2.2yrs	no data	no data
Angele Robinson-Gaylord	Senior Vice President of Store Development	3.6yrs	no data	no data
Christopher DuPaul	Executive Vice President	2.3yrs	no data	0.063% € 4.8k
Rand Greenblatt	Divisional Chief Financial & Administrative officer for Elixir	2.3yrs	no data	no data

2.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: RTA1's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Knowling	Independent Director	5.6yrs	US$264.55k	0% € 0
Arun Nayar	Independent Director	5.6yrs	US$270.00k	0.000050% € 3.8
Bruce Bodaken	Independent Chairman of the Board	11yrs	US$425.00k	0.012% € 900.7
Elizabeth Burr	Director	5.1yrs	US$858.46k	0% € 0
Carrie Teffner	Director	less than a year	no data	no data
Paul Keglevic	Director	less than a year	no data	no data
Bari Harlam	Independent Director	3.7yrs	US$272.63k	0% € 0
Katherine Quinn	Independent Director	5.1yrs	US$283.75k	0% € 0

5.1yrs

Average Tenure

64.5yo

Average Age

Experienced Board: RTA1's board of directors are considered experienced (5.1 years average tenure).

Rite Aid Management

Management criteria checks 2/4

Key information

Recent management updates

Rite Aid Corporation Announces Resignation of Jeffrey S. Stein, as Chief Restructuring Officer

Rite Aid Corporation Announces Board Appointments

Rite Aid Corporation Announces Executive Changes

Rite Aid Corporation, Annual General Meeting, Jul 26, 2023

Rite Aid Corporation, Annual General Meeting, Aug 18, 2023

Rite Aid Corporation Names Thomas Sabatino Chief Legal Officer

Recent updates

Rite Aid Corporation COM PAR Deleted from OTC Equity

Rite Aid Corporation Announces Resignation of Jeffrey S. Stein, as Chief Restructuring Officer

Rite Aid Announces Availability of Opill At All Locations

Motion for Asset Sale Approved for Rite Aid Corporation

Second Amended Reorganization Plan & Dsiclosure Statement Filed by Rite Aid Corporation

Rite Aid Corporation (OTCPK:RADC.Q) acquired Tuttles Pharmacy Inc from Pellegrini family.

Rite Aid Corporation announced delayed 10-Q filing

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Rite Aid Corporation Securities Litigation

Rite Aid Corporation Announces Board Appointments

Rite Aid Corporation(OTCPK:RADC.Q) dropped from S&P TMI Index

Rite Aid Corporation(OTCPK:RADC.Q) dropped from S&P Global BMI Index

NYSE Suspends Trading in Rite Aid

Rite Aid Corporation Filed for Bankruptcy

Rite Aid Corporation Filed for Bankruptcy

Rite Aid Corporation announced delayed 10-Q filing

Rite Aid Corporation Receives Written Notice from the New York Stock Exchange

Rite Aid Corporation is Heading Towards Bankruptcy

Rite Aid and Bartell Drugs Announce Availability of Appointments for Updated COVID-19 Vaccine

Rite Aid Announces Availability of OTC NARCAN Nasal Spray At All Locations

Rite Aid Corporation Announces Availability of Flu and RSV Vaccine Appointments at All Locations

New major risk - Share price stability

Rite Aid Corporation Announces Executive Changes

Rite Aid Corporation, Annual General Meeting, Jul 26, 2023

New minor risk - Shareholder dilution

Rite Aid Corporation, Annual General Meeting, Aug 18, 2023

First quarter 2024 earnings released: US$5.56 loss per share (vs US$2.03 loss in 1Q 2023)

Rite Aid Corporation(NYSE:RAD) dropped from Russell Small Cap Comp Growth Index

Rite Aid Corporation to Report Q1, 2024 Results on Jun 29, 2023

Rite Aid Corporation Names Thomas Sabatino Chief Legal Officer

Rite Aid Announces Launch of RYSHI Beauty and Personal Care Essentials

Elixir Announces the Next Wave of Innovation for Pharmacy Benefits Technology Platform

Full year 2023 earnings released: US$13.72 loss per share (vs US$9.96 loss in FY 2022)

Department of Justice Intervenes in Baron & Budd Whistleblower Lawsuit Against Rite Aid

Rite Aid Corporation Announces Departure of Heyward Donigan as President and as A Member of the Board

Third quarter 2023 earnings released: US$1.23 loss per share (vs US$0.67 loss in 3Q 2022)

Rite Aid Corporation Provides Earnings Guidance for the Fiscal Year 2023

Rite Aid Corporation to Report Q3, 2023 Results on Dec 21, 2022

Bronstein, Gewirtz & Grossman, LLC Notifies Rite Aid Corporation (RAD) Investors of Class Action and Encourages Investors to Actively Participate

Insufficient new directors

Bronstein, Gewirtz & Grossman, LLC Files Lawsuit Against Rite Aid Corporation and Certain of Its Officers

Rite Aid Corporation Investors with Substantial Losses Have Opportunity to Lead the Rite Aid Class Action Lawsuit

Rite Aid Corporation Announces Impairment Charges for the Second Quarter Ended August 27, 2022

Rite Aid Corporation Announces Executive Changes, Effective January 13, 2023

Rite Aid Corporation to Report Q2, 2023 Results on Sep 29, 2022

Rite Aid Scheduling for COVID-19 Boosters Now Available At Rite Aid and Bartell Drugs Locations

Rite Aid Corporation Announces Outlook for 2023

Rite Aid Corporation, Annual General Meeting, Jul 27, 2022

Rite Aid Corporation to Report Q1, 2023 Results on Jun 23, 2022

Spear Point Capital Management LLC cancelled the acquisition of Rite Aid Corporation (NYSE:RAD).

Full year 2022 earnings released: US$9.96 loss per share (vs US$1.87 loss in FY 2021)

Rite Aid Corporation Reports Impairment Charges for the Fourth Quarter Ended February 26, 2022

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age